Edwards idea of “lifetime” management., page-30

I'm not saying it should be "given away" for that price, just that it may be difficult to ignore (not accept) an offer like it.

Wayne has a fiduciary responsibility to shareholders and I believe it would be difficult for him (and the board) not to recommend a deal at 4-5x current share price. (All IMO)

The difference in current Market Cap, internal valuation and potential future valuation comes down to two things IMO, ability to execute and market perception. we saw with ADAPT / CardioCel just how difficult it is to break into these markets. You could argue CardioCel is 5-10x better than competing patches but uptake was still slow and sales difficult (IMO). TAVR has some advantages IMO bc price point and severity of condition being treated, however I'm still shocked CardioCel did not sell more given it should (in theory? practice?) prevent additional open heart surgeries for infants.

Basically I'm just saying this healthcare space is difficult, no walk in the park and $5bil+ valuations imply a lot of +ve cashflow (IMO).

I'm also trying to stay grounded, it's easy to get carried away and forget fundamentals